UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14D-9

(Amendment No. 7)

SOLICITATION/RECOMMENDATION STATEMENT

PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

WRIGHT MEDICAL GROUP N.V.

(Name of Subject Company)

 

 

WRIGHT MEDICAL GROUP N.V.

(Name of Person(s) Filing Statement)

 

 

Ordinary Shares, par value €0.03 per share

(Title of Class of Securities)

N96617118

(CUSIP Number of Ordinary Shares)

James A. Lightman

Senior Vice President, General Counsel and Secretary

Wright Medical Group N.V.

Prins Bernhardplein 200

1097 JB Amsterdam, The Netherlands

(+31) 20 521 4777

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications

on Behalf of the Person(s) Filing Statement)

With a copy to:

Zachary R. Blume

Paul M. Kinsella

Ropes & Gray LLP

Prudential Tower

800 Boylston Street

Boston, Massachusetts 02199

(617) 951-7000

 

 

 

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

 

 


This Amendment No. 7 (this “Amendment”) to Schedule 14D-9 amends and supplements the Schedule 14D-9 previously filed by Wright Medical Group N.V., a public limited liability company organized under the laws of the Netherlands (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”) on December 13, 2019 (as amended or supplemented from time to time, the “Schedule 14D-9”), with respect to the tender offer made by Stryker B.V., a private company with limited liability organized under the laws of the Netherlands (“Purchaser”), an indirect, wholly-owned subsidiary of Stryker Corporation, a Michigan corporation (“Stryker”), to purchase all of the outstanding ordinary shares, par value €0.03 per share, of the Company (the “Shares”) at a purchase price of $30.75 per Share without interest and less applicable withholding taxes, payable in cash to the holders thereof (such amount or any higher amount per Share paid pursuant to the Offer (as defined below), the “Offer Consideration”), on the terms and subject to the conditions set forth in the Offer to Purchase, dated December 13, 2019 (the “Offer to Purchase”), and in the related Letter of Transmittal (the “Letter of Transmittal” and, together with the Offer to Purchase, as each may be amended from time to time, the “Offer”). The Offer is described in a Tender Offer Statement on Schedule TO (the “Schedule TO”) filed by Stryker and Purchaser with the SEC on December 13, 2019, and the Offer to Purchase and the Letter of Transmittal have been filed as Exhibits (a)(1)(A) and (a)(1)(B) thereto, respectively, as each may be amended or supplemented from time to time.

Capitalized terms used in this Amendment but not defined herein shall have the respective meaning given to such terms in the Schedule 14D-9. The information set forth in the Schedule 14D-9 remains unchanged and is incorporated herein by reference, except that such information is hereby amended or supplemented to the extent specifically provided herein.

 

Item 8.

Additional Information

The disclosure in Item 8 of the Schedule 14D-9 under the subheading “Foreign Regulatory Filings” under the heading “(c) Regulatory Approvals and Other Approvals” is hereby amended and supplemented by adding the following paragraph as the second paragraph under the subheading “United Kingdom”:

“In May 2020, Stryker and Purchaser submitted a merger notice to the CMA. On June 30, 2020, the CMA announced the completion of its Phase 1 review of the acquisition. The CMA determined that the acquisition could result in a substantial lessening of competition in the market for total ankle replacement prosthesis products in the United Kingdom and will be referred for a Phase 2 investigation unless the parties offer acceptable undertakings to address the identified concerns. The deadline to propose potential undertakings is July 7, 2020, and the CMA has until July 14, 2020 to accept (in principle) or reject our proposed undertakings. Stryker and the Company will continue to work cooperatively with the CMA.”

 

 

2


SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated:  July 1, 2020

 

WRIGHT MEDICAL GROUP N.V.

 

By:

 

/s/  James A. Lightman

 

Name: 

 

James A. Lightman

 

Title:

 

Senior Vice President, General Counsel and Secretary

Wright Medical Group NV (NASDAQ:WMGI)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Wright Medical Group NV Charts.
Wright Medical Group NV (NASDAQ:WMGI)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Wright Medical Group NV Charts.